

This is a provisional PDF only. Copyedited and fully formatted version will be made available soon.

# REPORTS OF PRACTICAL ONCOLOGY AND RADIOTHERAPY

ISSN: 1507-1367

e-ISSN: 2083-4640

## **The impact of XPC gene single nucleotide polymorphism rs2228001 on head and neck cancer patients' response to radiotherapy treatment**

**Authors:** Bartosz Maćkowiak, Kamila Ostrowska, Katarzyna Kulcenty, Joanna Kaźmierska, Julia Ostapowicz, Hanna Nowicka, Mateusz Szewczyk, Krzysztof Książek, Wiktoria Maria Suchorska, Wojciech Golusiński

**DOI:** 10.5603/rpor.99676

**Article type:** Research paper

**Published online:** 2024-03-09

This article has been peer reviewed and published immediately upon acceptance. It is an open access article, which means that it can be downloaded, printed, and distributed freely, provided the work is properly cited.



# The impact of *XPC* gene single nucleotide polymorphism rs2228001 on head and neck cancer patients' response to radiotherapy treatment

[10.5603/rpor.99676](#)

Bartosz Maćkowiak<sup>1-3</sup>, Kamila Ostrowska<sup>1, 2</sup>, Katarzyna Kulcenty<sup>2</sup>, Joanna Kaźmierska<sup>4, 5</sup>, Julia Ostapowicz<sup>1, 2, 5</sup>, Hanna Nowicka<sup>3</sup>, Mateusz Szewczyk<sup>1</sup>, Krzysztof Książek<sup>6</sup>, Wiktoria M. Suchorska<sup>2, 5</sup>, Wojciech Golusiński<sup>1</sup>

<sup>1</sup>*Department of Head and Neck Surgery, Poznan University of Medical Sciences, Poznan, Poland*

<sup>2</sup>*Radiobiology Laboratory, The Greater Poland Cancer Centre, Poznan, Poland*

<sup>3</sup>*Faculty of Medicine, Poznan University of Medical Sciences, Poznan, Poland*

<sup>4</sup>*Radiotherapy Department II, The Greater Poland Cancer Centre, Poznan, Poland*

<sup>5</sup>*Department of Electroradiology, Poznan University of Medical Sciences, Poznan, Poland*

<sup>6</sup>*Department of Pathophysiology of Ageing and Civilization Diseases, Poznan University of Medical Sciences, Poznan, Poland*

**Corresponding author:** Bartosz Maćkowiak, Department of Head and Neck Surgery, Poznan University of Medical Sciences, 61-866 Poznan, Poland; e-mail: barmackowiak@gmail.com

## Abstract

**Background:** Head and neck squamous carcinoma (HNSC) is the sixth most common neoplasm, with a 40–50% overall survival rate. HNSC standard treatment depends on tumor size, metastasis or human papillomavirus (HPV) status including surgery, chemotherapy, and radiotherapy. The last two may lead to defects in the tumor microenvironment and cancer cell biology as disorders in DNA damage repair systems.

Here, we evaluate the correlation between single nucleotide polymorphism (SNP) rs2228001 in the *XPC* gene with the early and late adverse effects of radiotherapy, determine the distribution of the SNP and post-treatment follow-up in HNSC patients.

**Materials and methods:** Head and neck cancer tissues and clinical data were obtained from 79 patients. The SNP of the *XPC* gene (rs2228001) was evaluated with polymerase chain reaction — restriction fragment length polymorphism (PCR-RFLP). The chi-square test was used to determine the correlation between mutation and adverse effects occurrence.

**Results:** Single nucleotide polymorphism rs2228001 in the *XPC* gene is correlated with the early adverse effect of skin reaction and the late adverse effect of elevated C-reactive protein (CRP) levels in the HNSC patients.

**Key words:** head and neck cancer; XPC; damage repair systems; radiotherapy; adverse effects

## Introduction

Head and neck squamous carcinomas (HNSC) are a group of neoplasms occurring in the oral cavity, pharynx, salivary glands and larynx. HNSC risk factors include tobacco usage, alcohol abuse, inefficient oral hygiene, or human papillomavirus (HPV) type 16 or 18 infection [1]. The disease's first alarming symptoms may be an irregular and painless protrusion, ulcerations, or leukoplakia in the head and neck area. Prediction data suggests a rise in the number of incidents, especially in younger populations, with a 30% annual increase in incidence by 2030 [2]. Nevertheless, HNSC affects more than 600,000 people per year worldwide [3]. Treatment of HNSC is complex and depends on primary site of tumor, TNM staging, and individual patient performance status. In general, surgery, chemotherapy (CT), radiotherapy (RT), and immunotherapy (IO) in various combinations are used [4]. Patients after treatment require a long time for recovery, including time after treatment and rehabilitation [5]. Postoperative RT is recommended if a patient has one or more risk factors of relapse, such as a positive or close surgical margin, multiple positive lymph nodes, extranodal extension of cancer and often if in advanced local stage. After completion of radiotherapy course, patients may suffer from adverse effects (AE) such as skin or mucosa fibrosis or even ulceration. Moreover, xerostomia, leukopenia, higher C-reactive protein (CRP) levels, among others, are observed after radiotherapy [6, 7]. Radiotherapy impacts the tumor microenvironment (TME) since it can induce both immune suppressive and proinflammatory effects. The seriousness of changes in TME depends on many factors, and it is likely correlated with chronic inflammation of the irradiated site [8, 9]. Despite many studies on patients' clinical material, such as tumor and blood, we still cannot identify direct

specific markers of disease progression and response to treatment. SNPs are promising candidates for markers due to quick and simple analysis and reported influence on cancer prognosis [10, 11]. The *XPC* (XPC complex subunit, DNA damage recognition and repair factor) gene participates in the global genome nucleotide excision repair (GG-NER) system that repairs the mismatched nucleotides. To initiate the GG-NER process, XPC protein forms a complex, which recognizes the DNA point mutations [12]. Scientific reports suggest that disturbances in the NER system may influence carcinogenesis in the premalignant state as oral lesions [13] and promote tumor growth in the cervix [11], genitourinary system [10] and breast [14]. The SNP rs2228001 that occurs in the *XPC* gene causes the substitution of adenine to cytosine on at least one of the chromosome arms. This point mutation yields to of exchanging the 939<sup>th</sup> amino acid lysine to glutamine. Previous reports suggest that SNP rs2228001 can be responsible for higher morbidity and worse AE during and after the treatment [11]. Hence, this study aims to assess the correlation of the SNP rs2228001 occurrence with adverse late effects after radiotherapy to indicate genetic markers for monitoring AE's progression and predict the treatment's outcome. Here, we investigate whether the SNP of the *XPC* gene may be a biomarker for predicting radiotherapy treatment response and adverse events after radiotherapy.

## **Materials and methods**

### ***Patient material***

Head and neck squamous carcinoma tissues were collected from 79 patients from Greater Poland who underwent surgical tumor resection in the Department of Head and Neck Surgery, Poznan University of Medical Sciences, The Greater Poland Cancer Centre. Radiotherapy and AEs data was collected retrospectively from patients' medical records. Samples were immediately frozen and stored at –80°C until DNA isolation. The inclusion criteria involved diagnosed squamous cancer of oral cavity or larynx. The exclusion criteria for this study involved a distant metastasis, a second primary tumor, and HPV infection. The procedures were approved by the Local Ethical Committee of Poznan University of Medical Sciences (Consent no. 121/23). The characteristics of the study group are presented in Table 1.

### ***Material homogenization and DNA isolation***

Tumor tissues were homogenized with mortar and pestle with the liquid nitrogen and subsequently used for DNA extraction. Genomic DNA was extracted using a DNA

Mammalian Genomic Purification Kit from Sigma-Aldrich Co. (St. Louis, USA). The concentration and purity of the isolated DNA was assessed using the spectrophotometric method. Quality Control (QC) metrics for DNA purity means are  $\bar{X}_{A260/280} = 1.74 \pm 0.16$  and  $\bar{X}_{A260/230} = 1.64 \pm 0.54$ .

### ***Restriction fragments length polymorphism (RFLP)***

The KAPA HiFi HotStart ReadyMix (Roche, Switzerland) was used to perform polymerase chain reaction (PCR) amplification of the *XPC* gene containing the rs2228001 fragment (281 bp). Each 25  $\mu$ L reaction contains 12.5  $\mu$ L 2X KAPA HiFi HotStart Ready Mix, 10  $\mu$ M of forward and reverse primers, 100 ng of the DNA template and PCR-grade water. The amplification started with an initial denaturation at 95°C for 3 min, 35 cycles containing denaturation 95°C for 20s, annealing 60°C for 15 s, and elongation at 72°C for 30s, followed by final extension in 72°C for 30s. The primer sequences are presented in Supplementary Table 1. For *XPC* amplicon restriction digestion, we used *PvuII* (ThermoFisher, USA). Each 31  $\mu$ L reaction contains 10  $\mu$ L of PCR reaction products, 2  $\mu$ L 10X buffer G, 1  $\mu$ L *PvuII* and an appropriate volume of PCR-grade water. Incubation lasts for 2 hours. To inactivate the enzyme, 0.5 M EDTA pH 8.0, with a final concentration of 20 mM, was used. To determine the presence of SNP rs2228001 in the *XPC* gene, we performed electrophoresis in 2% agarose gel with the addition of the ethidium bromide in 1X TAE buffer; DNA bands were visualized using UV light in the ChemiDoc™ Touch Imaging System (Bio-Rad, USA). The result of gel electrophoresis is presented in the Supplementary Figure 1. The expected fragment size of the AA genotype was 281 bp, CA 131, 150, 281 bp, and CC 131, 150 bp, respectively.

### ***Adverse effects grading***

The grade of early adverse effects occurring during radiotherapy was assessed by radiotherapy specialists, based on standardized scales Common Terminology Criteria Adverse Events (CTCAE) v5 and World Health Organization (WHO) (Supplementary File — Tab. S2). Late adverse effects were classified using the CTCAE v5.0 scale. Additionally, CRP concentration was tested. CRP level > 5 mg/L was assumed elevated, according to laboratory normal range.

### ***Statistics***

The distribution of genotypes was tested for the Hardy-Weinberg equilibrium (HWE) using the  $\chi^2$  test (HWE asymptotic significance = 0.134). The association between SNPs and early

and late adverse effects was estimated using the  $\chi^2$  test with Fisher's exact test (the observed numbers was  $\leq 10$  or one of the expected numbers was  $< 5$ ). A two-sided  $p < 0.05$  was regarded as significant.

## Results

### ***Single nucleotide polymorphism rs2228001 distribution and HNSC patients' follow-up***

A total group of 79 patients with HNSC was recruited for the study. Figure 1. presents the distribution of SNP in a group of patients included in the study. 34% of patients represented unchanged variant of nucleotides (AA), and 66% had at least one mutation (58% AC; 8% CC). Moreover, we determined that tumor and paired-matched margin tissue had identical mutations (Supplementary File — Fig. S2).

To test whether the presence of the mutation affects HNSC patients' survival, we performed a Kaplan-Meier analysis. The follow-up was measured by the period from surgery to the last check-up or death, whatever came first. The Kaplan-Meier curve showed no significant difference ( $p > 0.05$ ) between groups, the mean survival rate for patients with the AA variant equaled 764 days, 781days for the AC variant and 311 days for the CC variant (Fig. 1).

### ***SNP rs2228001 occurrence has an impact on HNSC patients' post radiotherapy response effect adverse effects***

Adverse effects of radiation can be divided according to the time of their occurrence. Early AEs present as dermatitis of skin of the neck and mucositis of the oral cavity and /or throat. Late AEs include chronic pain, fibrosis, xerostomia, lymphopenia, and CRP concentration. The chi-square test was performed, and it confirmed a correlation between mutation occurrence and early AE on patients' skin ( $p = 0.033$ ) and late AE in elevated CRP levels ( $p = 0.030$ ). The rest of the parameters measured were not correlated significantly ( $p > 0.05$ ). The entire analysis is presented in Table 2.

Amongst patients with early AE on the skin ( $n = 24$ ), 75% ( $n = 18$ ) had the mutation. Late adverse effects of elevated CRP levels amongst the research group ( $n = 16$ ) were presented by 44% ( $n = 7$ ) of patients, and 29% ( $n = 2$ ) of them had mutation (Fig. 2).

## Discussion

Head and neck cancer morbidity is still rising year by year. Oncological treatment, such as radiotherapy, is very effective but also induces tissue, cellular and molecular damage in healthy tissues. Ionizing radiation directly damages the DNA helix by creating DNA breaks such as single or double strand breaks, generation of reactive oxygen species [15]. Surgery and RT are often considered as equal [3]. Technological upgrades of radiotherapy systems contributed to more beneficial outcome for patients due to scoring lower grades during AEs assessment [16].

Numerous studies prove increasing importance of DNA repair systems, especially in cancers therapy [17–19]. A better understanding of DNA repair systems may be crucial to describe novel biomarkers of morbidity or treatment response. Some studies suggest that overexpression of DNA repair systems related genes such as XPC (that participate in NER mechanism) may be a cause of platin-based drugs resistance [20]. Moreover, the higher expression level of various NER-related genes leads to a decrease in the efficiency of platinum-based therapies in stomach [21], colon [22] and lung [23] cancers. However, head and neck cancers response to treatment have not yet been linked with *XPC* gene mutation occurrence. Cisplatin-based therapy has a similar molecular outcome as radiotherapy – both create DNA lesions; platin-based compounds have crosslinking properties, while irradiation creates bulks on DNA strands. XPC is responsible for DNA damage recognition, thus initiating the entire repair process [24].

Here, we assess the occurrence of *XPC* gene SNP rs2228001 in 79 patients with HNSC using the polymerase chain reaction — restriction fragment length polymorphism (PCR-RFLP) method and correlate the data with adverse effects during and after irradiation. Our results showed the correlation between the appearance of AC/CC mutation, early AE on the skin, and late AE of elevated CRP levels. However, difference in mean survival rate in Kaplan-Meier should be considered with caution due to differences in sizes of groups (CC variant has only 6 patients).

The mechanism of radiation-induced dermatitis is also related to DNA damage and impaired mitosis. Combined with a defective NER system, patients with AC or CC rs2228001 *XPC* gene mutations have a higher probability of suffering from more advanced skin reactions after irradiation, which can deteriorate the quality of life. Due to irradiation, CRP levels may be



higher due to the local inflammation process. Both cases suggest the DNA structure is damaged due to NER insufficient activity.

## **Conclusions**

Our results indicate that XPC-deficient patients may have weakened DNA repair systems and, thus, have worse responses to radiotherapy treatment. An identical set of mutations in one patient in both types of material suggests that mutation is not gained during the carcinogenesis process. Yet, more studies are needed to confirm if these mutation symptoms apply to every cancer type. Both significant adverse effects are important factors in a patient's condition assessment during treatment.

In conclusion, this work contributes to understanding the impact of the XPC gene in radiotherapy treatment in HNSC patients. It presents the knowledge useful to work on future biomarkers of radiotherapy treatment response and personalised oncological approach.

## ***Conflicts of interest***

None declared.

## ***Funding***

This publication was prepared without any external source of funding.

## ***Acknowledgements***

None declared.

## **References**

1. Barsouk A, Aluru JS, Rawla P, et al. Epidemiology, Risk Factors, and Prevention of Head and Neck Squamous Cell Carcinoma. *Med Sci (Basel)*. 2023; 11(2), doi: [10.3390/medsci11020042](https://doi.org/10.3390/medsci11020042), indexed in Pubmed: [37367741](https://pubmed.ncbi.nlm.nih.gov/37367741/).
2. Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. *CA Cancer J Clin*. 2021; 71(3): 209–249, doi: [10.3322/caac.21660](https://doi.org/10.3322/caac.21660), indexed in Pubmed: [33538338](https://pubmed.ncbi.nlm.nih.gov/33538338/).
3. Bray F, Colombet M, Mery L, Piñeros M. et al. (ed). *Cancer Incidence in Five Continents*. Vol XI. IARC Publications 2021.
4. Machiels JP, René Leemans C, Golusinski W, et al. EHNS Executive Board. Electronic address: [secretariat@ehns.org](mailto:secretariat@ehns.org), ESMO Guidelines Committee. Electronic address: [clinicalguidelines@esmo.org](mailto:clinicalguidelines@esmo.org), ESTRO Executive Board. Electronic address: [info@estro.org](mailto:info@estro.org). Squamous cell carcinoma of the oral cavity, larynx, oropharynx and hypopharynx: EHNS-ESMO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol*.

2020; 31(11): 1462–1475, doi: [10.1016/j.annonc.2020.07.011](https://doi.org/10.1016/j.annonc.2020.07.011), indexed in Pubmed: [33239190](https://pubmed.ncbi.nlm.nih.gov/33239190/).

5. Allgar VL, Oliver SE, Chen H, et al. Time intervals from first symptom to diagnosis for head and neck cancers: An analysis of linked patient reports and medical records from the UK. *Cancer Epidemiol.* 2019; 59: 37–45, doi: [10.1016/j.canep.2019.01.008](https://doi.org/10.1016/j.canep.2019.01.008), indexed in Pubmed: [30669114](https://pubmed.ncbi.nlm.nih.gov/30669114/).
6. Brook I. Early side effects of radiation treatment for head and neck cancer. *Cancer Radiother.* 2021; 25(5): 507–513, doi: [10.1016/j.canrad.2021.02.001](https://doi.org/10.1016/j.canrad.2021.02.001), indexed in Pubmed: [33685809](https://pubmed.ncbi.nlm.nih.gov/33685809/).
7. Brook I. Late side effects of radiation treatment for head and neck cancer. *Radiat Oncol J.* 2020; 38(2): 84–92, doi: [10.3857/roj.2020.00213](https://doi.org/10.3857/roj.2020.00213), indexed in Pubmed: [33012151](https://pubmed.ncbi.nlm.nih.gov/33012151/).
8. Monjazeb AM, Schalper KA, Villarroel-Espindola F, et al. Effects of Radiation on the Tumor Microenvironment. *Semin Radiat Oncol.* 2020; 30(2): 145–157, doi: [10.1016/j.semradonc.2019.12.004](https://doi.org/10.1016/j.semradonc.2019.12.004), indexed in Pubmed: [32381294](https://pubmed.ncbi.nlm.nih.gov/32381294/).
9. Barker HE, Paget JTE, Khan AA, et al. The tumour microenvironment after radiotherapy: mechanisms of resistance and recurrence. *Nat Rev Cancer.* 2015; 15(7): 409–425, doi: [10.1038/nrc3958](https://doi.org/10.1038/nrc3958), indexed in Pubmed: [26105538](https://pubmed.ncbi.nlm.nih.gov/26105538/).
10. Wu C, Xu C, Wang G, et al. Noninvasive circulating tumor cell and urine cellular (rs2228001, A2815C) and (rs25487, G1196A) polymorphism detection as an effective screening panel for genitourinary system cancers. *Transl Cancer Res.* 2019; 8(8): 2803–2812, doi: [10.21037/tcr.2019.10.47](https://doi.org/10.21037/tcr.2019.10.47), indexed in Pubmed: [35117037](https://pubmed.ncbi.nlm.nih.gov/35117037/).
11. Das S, Naher L, Aka TD, et al. The rs11615, rs2276466, rs2228000 and rs2228001 polymorphisms increase the cervical cancer risk and aggressiveness in the Bangladeshi population. *Heliyon.* 2021; 7(1): e05919, doi: [10.1016/j.heliyon.2021.e05919](https://doi.org/10.1016/j.heliyon.2021.e05919), indexed in Pubmed: [33490679](https://pubmed.ncbi.nlm.nih.gov/33490679/).
12. Leibel D, Laspe P, Emmert S. Nucleotide excision repair and cancer. *J Mol Histol.* 2006; 37(5-7): 225–238, doi: [10.1007/s10735-006-9041-x](https://doi.org/10.1007/s10735-006-9041-x), indexed in Pubmed: [16855787](https://pubmed.ncbi.nlm.nih.gov/16855787/).
13. Wang Y, Spitz MR, Lee JJ, et al. Nucleotide excision repair pathway genes and oral premalignant lesions. *Clin Cancer Res.* 2007; 13(12): 3753–3758, doi: [10.1158/1078-0432.CCR-06-1911](https://doi.org/10.1158/1078-0432.CCR-06-1911), indexed in Pubmed: [17575242](https://pubmed.ncbi.nlm.nih.gov/17575242/).
14. He BS, Xu T, Pan YQ, et al. Nucleotide excision repair pathway gene polymorphisms are linked to breast cancer risk in a Chinese population. *Oncotarget.* 2016; 7(51): 84872–84882, doi: [10.18632/oncotarget.12744](https://doi.org/10.18632/oncotarget.12744), indexed in Pubmed: [27768589](https://pubmed.ncbi.nlm.nih.gov/27768589/).
15. Li B, Yabluchanskiy A, Tarantini S, et al. Measurements of cerebral microvascular blood flow, oxygenation, and morphology in a mouse model of whole-brain irradiation-induced cognitive impairment by two-photon microscopy and optical coherence tomography: evidence for microvascular injury in the cerebral white matter. *Geroscience.* 2023; 45(3): 1491–1510, doi: [10.1007/s11357-023-00735-3](https://doi.org/10.1007/s11357-023-00735-3), indexed in Pubmed: [36792820](https://pubmed.ncbi.nlm.nih.gov/36792820/).
16. Mohamed AE, Hassouna AH, Mosalum HS, et al. The outcome of early-stage glottic carcinoma patients treated with radiotherapy: Egyptian National Cancer Institute (NCI-Egypt) experience. *Rep Pract Oncol Radiother.* 2023; 28(4): 496–505, doi: [10.5603/RPOR.a2023.0052](https://doi.org/10.5603/RPOR.a2023.0052), indexed in Pubmed: [37795222](https://pubmed.ncbi.nlm.nih.gov/37795222/).
17. Marteiijn JA, Lans H, Vermeulen W, et al. Understanding nucleotide excision repair and its roles in cancer and ageing. *Nat Rev Mol Cell Biol.* 2014; 15(7): 465–481, doi: [10.1038/nrm3822](https://doi.org/10.1038/nrm3822), indexed in Pubmed: [24954209](https://pubmed.ncbi.nlm.nih.gov/24954209/).
18. Rajabi-Moghaddam M, Abbaszadeh H. Gene polymorphisms and risk of head and neck squamous cell carcinoma: a systematic review. *Rep Pract Oncol Radiother.* 2022; 27(6): 1058–1076, doi: [10.5603/RPOR.a2022.0115](https://doi.org/10.5603/RPOR.a2022.0115), indexed in Pubmed: [36632298](https://pubmed.ncbi.nlm.nih.gov/36632298/).

19. Kozłowska-Masłoń J, Guglas K, Kolenda T, et al. miRNA in head and neck squamous cell carcinomas: promising but still distant future of personalized oncology. *Rep Pract Oncol Radiother.* 2023; 28(5): 681–697, doi: [10.5603/rpor.96666](https://doi.org/10.5603/rpor.96666), indexed in Pubmed: [38179293](https://pubmed.ncbi.nlm.nih.gov/38179293/).
20. Duan M, Ulibarri J, Liu KeJ, et al. Role of Nucleotide Excision Repair in Cisplatin Resistance. *Int J Mol Sci.* 2020; 21(23), doi: [10.3390/ijms21239248](https://doi.org/10.3390/ijms21239248), indexed in Pubmed: [33291532](https://pubmed.ncbi.nlm.nih.gov/33291532/).
21. Pajuelo-Lozano N, Bargiela-Iparraguirre J, Dominguez G, et al. XPA, XPC, and XPD Modulate Sensitivity in Gastric Cisplatin Resistance Cancer Cells. *Front Pharmacol.* 2018; 9: 1197, doi: [10.3389/fphar.2018.01197](https://doi.org/10.3389/fphar.2018.01197), indexed in Pubmed: [30386247](https://pubmed.ncbi.nlm.nih.gov/30386247/).
22. Zhang Yi, Cao J, Meng Y, et al. Overexpression of xeroderma pigmentosum group C decreases the chemotherapeutic sensitivity of colorectal carcinoma cells to cisplatin. *Oncol Lett.* 2018; 15(5): 6336–6344, doi: [10.3892/ol.2018.8127](https://doi.org/10.3892/ol.2018.8127), indexed in Pubmed: [29616110](https://pubmed.ncbi.nlm.nih.gov/29616110/).
23. Teng X, Fan XF, Li Qi, et al. XPC inhibition rescues cisplatin resistance via the Akt/mTOR signaling pathway in A549/DDP lung adenocarcinoma cells. *Oncol Rep.* 2019; 41(3): 1875–1882, doi: [10.3892/or.2019.6959](https://doi.org/10.3892/or.2019.6959), indexed in Pubmed: [30628719](https://pubmed.ncbi.nlm.nih.gov/30628719/).
24. Friedberg EC. How nucleotide excision repair protects against cancer. *Nat Rev Cancer.* 2001; 1(1): 22–33, doi: [10.1038/35094000](https://doi.org/10.1038/35094000), indexed in Pubmed: [11900249](https://pubmed.ncbi.nlm.nih.gov/11900249/).

**Table 1.** The clinical characteristics of the study cohort

Characteristic	Total number	%
Patients number	79	
<b>Age at the time of surgery (years)</b>		
Mean	64	
Median	65	
Range	36-90	
<b>Gender</b>		
Female	24	30%
Male	55	70%
<b>TNM classification</b>		
T1	3	4%
T2	17	21%
T3	31	40%
T4	28	35%
N0	28	35%
N1	19	24%
N2	22	28%
N3	10	13%
M0	79	100%
<b>Histologic grade</b>		
G1	13	16%
G2	52	66%

G3	14	18%
<b>Anatomical site</b>		
Oral cavity	58	74%
Larynx	21	26%
<b>Smoking</b>		
Yes	54	68%
No	24	32%
<b>Alcohol</b>		
Yes	17	22%
No	61	78%
<b>SNP Variant</b>		
AA	27	34%
AC	46	58%
CC	6	8%
<b>Adjuvant treatment</b>		
None	19	24%
Radiotherapy	25	32%
Chemoradiotherap y	35	44%

TNM — tumor–node–metastasis; SNP — single nucleotide polymorphism


**Table 2.** Association between single nucleotide polymorphism (SNPs) and early and late adverse effects in the chi-square analysis

	<b>Chi-square test</b>			<b>Chi-square test</b>	
<b>Radiotherapy</b>	Value	Fisher exact test asymptotic significance (2-sided)	<b>Chemoradiotherapy</b>	value	Fisher exact test asymptotic significance (2-sided)
Early adverse effects			Early adverse effects		
Skin	8,505	<b>0,033 *</b>	Skin	5,309	0,659
Mucosa	3,644	0,458	Mucosa	3,341	0,557
Late adverse effects			Late adverse effects		
Fibrosis	0,751	1,000	Fibrosis	2,548	1,000
Pain	3,543	1,000	Pain	8,105	0,188


Xerostomia	2,978	1,000	Xerostomia	1,360	1,000
LLN decreased	6,320	0,436	LLN decreased	5,448	0,198
Elevated CRP	5,864	<b>0,030 *</b>	Elevated CRP	1,343	0,784

CRP — C-reactive protein; **LLN**

**Figure 1.** Kaplan-Meier curve representing the survival of the patients with single nucleotide polymorphism (SNP) rs2228001. There were 27 patients with AA variant, 46 with AC and 6 with CC, respectively



**Figure 2.** Cluster bars charts of significant associations between XPC gene SNP rs2228001 occurrence (AA — wildtype) and early (**A**) and late (**B**) adverse effects in radiotherapy-treated patients according to scale score a) assessing their skin condition (Supplementary File — Tab. S2) and **B**) 0 — C-reactive protein (CRP) < 5 mg/L; 1 — CRP > 5 mg/L



## Supplementary File


**Table S1.** Primers sequence

XPC reverse	CTGCCTCAGTTTGCCTTCTC
XPC forward	ACCAGCTCTCAAGCAGAAGC


**Table S2.** Early adverse effects grading scale

Grade	Skin description	Mucosa description
1	Subtle erythema, epilation, dry desquamation	Soreness, erythema, painless ulcers
2	Moderate erythema and edema, dermatitis in plaques,	A painful lesion with the ability to swallow, patchy reaction
3	Exudative dermatitis, intense edema	Ulcers, erythema, and edema which unable swallowing
4	Hemorrhage, necrosis, ulceration	Severe ulcers, necrosis, bleeding

# Occurrence of SNP rs2228001 in HNSC patients



**Figure S1.** Distribution of mutation amongst the patients. AA genotype comprises 34%, AC 58% and CC 8%, respectively



**Figure S2.** Example of gel electrophoresis performed on 5 patients' tumor and histopathologically unchanged tissues to confirm that tumor and unchanged margin samples present the same set of nucleotides. T — tumor sample; H — margin sample; numbers 1-5 are patients ID. Numbers on the right correspond to the length of DNA strands, where 280 base pairs refer to the A variant (uncut), 150 and 131 to the C variant (after cutting). The expected fragment size of the AA genotype was 281 bp, CA 131, 150, 281 bp, and CC 131, 150 bp, respectively

